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Background: Mumps virus (MuV) is a highly infectious paramyxovirus closely related to measles virus (MeV).
Despite the availability of a mumps vaccine, outbreaks continue to occur and no treatment options are available.
Vitamin A and other naturally occurring retinoids inhibit the replication of MeV in vitro.
Methods: Anti-viral effects of retinoids were observed in cell culture using the myelomonocytic U937, NB4/R4, and
Huh7/7.5 cells. Observations of anti-viral effect were quantified using TCID50 analysis. Molecular properties of the
antiviral effect were analysed using quantitative RT-PCR and western blot.
Results: The current work demonstrates that retinoids inhibit MuV in vitro due to up-regulation of type I interferon
(IFN) and IFN stimulated genes. This effect is mediated by nuclear retinoid receptor signalling and RIG-I is required.
The antiviral retinoid-induced state makes cells less permissive to viral replication from subsequent challenge with
either MuV or MeV for less than 12 hours.
Conclusions: These results demonstrate that retinoids inhibit MuV replication in uninfected bystander cells through
a retinoid inducible gene I (RIG-I), retinoic acid receptor (RAR) and IFN dependent manner making them refractory
to subsequent rounds of viral replication. These observations raise the possibility that pharmacological doses of
retinoids might have clinical benefit in MuV infection.Text
The Paramyxoviridae are single stranded, enveloped,
negative sense RNA viruses. They are among the most
important viral pathogens of humans and animals. Many
of the Paramyxoviridae replicate only in the respiratory
epithelium, but Morbillivirus and Rubulavirus members
typically have wider tissue tropism and can cause severe,
systemic disease [1]. Paramyxovirdae epidemics in virgin
populations can be devastating [1]. Vaccines are available
for only a small number of the Paramyxoviridae and
antiviral drugs are not yet available for most of these agents.
Mumps virus (MuV) is a Rubulavirus in the Paramyxo-
viridae family. It is the causative agent of mumps [2].
MuV is a highly contagious infection of humans and was
historically one of the most common childhood illnesses.
The virus infects and replicates in the nasal mucosa
and upper-respiratory tract [2]. A transient cell-associated* Correspondence: brian.ward@mcgill.ca
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reproduction in any medium, provided the orviremia (of mononuclear cells) contributes to systemic
viral spread [2]. In young children, MuV infection is typically
a mild disease characterized by fever, headache and swelling
of the salivary glands. Complications such as meningitis,
encephalitis or orchitis may occur. Mumps is a leading
cause of acquired sensorineural deafness among children.
Rates of post-infectious meningoencephalitis can be 1-10%
of clinical mumps cases. Although the fatality rate of mumps
encephalitis is low (0.1-0.5% of clinical mumps cases), the
risk of permanent neurologic sequelae in encephalitis cases is
25% [3]. Furthermore, MuV infection during the first
trimester of pregnancy is associated with a 25% incidence
of spontaneous abortion [3].
There is no current treatment for mumps other than
supportive care [2]. Vaccination programs in developed
countries have markedly increased the average age at
which clinical mumps occurs and dramatically reduced
the incidence of mumps infection [2]. Unfortunately,
large outbreaks have recently occurred in Europe, North
America, Australia and Israel [4–12].
In the last 2 decades, many studies have documented
the beneficial effects of vitamin A supplements on general
mortality and/or morbidity in young children in a wided. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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eight studies demonstrated an overall 30% reduction in
infant mortality attributable to vitamin A supplements
[13–15]. A surprising spin-off from these vitamin A
supplementation studies was the re-discovery that vitamin A
‘treatment’ can significantly decrease the morbidity
and mortality associated with acute MeV infection
[16–19]. The mechanism underlying the positive effects of
vitamin A supplements and treatment in measles are not
well understood [13]. Since the mid-1990s, the WHO and
UNICEF have recommended vitamin A treatment for
acute measles in regions of the developing world with high
mortality rates [20].
Vitamin A (retinol) is a fat-soluble vitamin. Its natural
and synthetic derivatives as well as metabolites are
collectively referred to as retinoids [21,22]. Retinol is
obtained from the diet as either retinyl esters or carotenoids.
Retinoids are required for a wide-range of crucial biological
processes including regulation of embryonic development,
maintenance of the integrity of epithelial cell surfaces, vision
and immunity [23]. The metabolite, all-trans retinoic acid
(ATRA) is responsible for mediating many of the important
biological functions of retinoids [22]. ATRA is the natural
ligand for retinoic acid receptors (RAR), which form hetero-
dimers with the retinoid X receptors (RXR) within the
nucleus [24]. RAR-RXR heterodimers bind to retinoic acid
response elements (RARE) on the promoters of target genes
to activate transcription when bound by ligand [21,22,24].
The protein products of retinoid-responsive genes are
responsible for exerting the effects of retinoids in the cell.
Retinoids have been shown to play a role in innate
immune responses and to regulate the expression of a
number of interferon stimulated genes [25–27]. Of
particular interest among the retinoid-responsive genes is
the type I interferon (IFN) pathway. A powerful trigger for
type I IFN production is the recognition of virus-associated
molecular patterns by pattern recognition receptors [28].
These cytokines trigger a rapid and strong innate defense
against many viruses, leading to the transcription of several
hundred ISGs controlled by the IFN-stimulated gene factor
3 (ISGF3) complex [29].
Of particular importance to the current work, retinoids
have specifically been implicated in regulating expression of
the ISG (Interferon Stimulated Gene) retinoid-inducible gene
I (RIG-I) and IFN regulatory factor 1 (IRF-1) [30–39]. RIG-I
is a pattern recognition receptor that was originally under-
stood to detect 5’-triphosphorylated, single-stranded RNA
[40–42] and is expressed at a basal level in many cell types.
The current consensus is that the minimal requirement for
RIG-I activation is a blunt-ended base paired RNA 10-20 bp
long with a 5’ triphosphate [43]. It can initiate the production
of type I IFN and is itself an ISG [44]. IFN has been
reported to induce RIG-I expression by causing the IRF-1
transcription factor to bind to the RIG-I promoter [45].Anti-MeV effects of retinoids have been observed in a
number of primary human cells and cell lines of diverse
tissue origin [46–48], including the myelomonocytic
U937 cells, which were an important model for our work
with MuV presented herein. We hypothesize that ATRA
treatment during other viral infections would also have
an antiviral effect. We set out to test whether or not
MuV replication could be inhibited by retinoids. Based
on our previous studies, we hypothesize that retinoids
would inhibit MuV replication in vitro and that this
inhibition would depend upon RAR signalling, type I
interferon and functional RIG-I.
Results
Mumps virus can be inhibited in vitro
U937 cells are neoplastic and histiocytic progenitors of
monocytes that have been extensively used in immunological
studies [49] including investigation of interferon pathways
during MuV infection [50–52]. In these cells, increasing
doses of retinol resulted in a significant inhibition of MuV
replication as quantified by TCID50 (Figure 1A). Significant
inhibition was achieved at concentrations as low as 1 μM, a
dose at which increased expression of the retinoid responsive
gene RARβ is readily observed (Figure 1C) [53]. Treatment
of U937 cells with increasing doses of ATRA was even more
effective as an inhibitor of MuV output (Figure 1B) and in
the induction of RARβ mRNA expression (Figure 1D) [53].
All subsequent investigations of the antiviral effect of
retinoids on MuV were performed using ATRA at a
dose of 1 μM.
Retinoid treatment enhances IFN signalling
The innate immune response is thought to be responsible
for the initial control of infectious agents. It has long been
known that up-regulation of the type I IFN response
functions in an auto-response feedback loop that is critically
important for antiviral responses. In the U937 model, MuV
infection alone is able to induce the expression of IFNα1
mRNA (Figure 2A). However, ATRA treatment of MuV
infected cells synergistically increases the expression of
IFNα1 mRNA and supernatant protein levels (Figure 2A-B).
IFNβ mRNA expression and protein levels are also
synergistically increased by the combined treatment of
ATRA and MuV infection (Figure 2C-D).
The increased type I IFN production leads to the
expression of ISGs. In the U937 model, IRF-1 mRNA
expression is significantly increased over control by
ATRA treatment alone (Figure 2E), in agreement with
our previous work [47] and the literature [30,38,39].
However, treatment of MuV infected cells with ATRA
further increases the expression of IRF-1 mRNA
(Figure 2E). This combined treatment (MuV + ATRA)
resulted in a robust increase in RIG-I mRNA expression




























Figure 1 In vitro inhibition of mumps virus by retinoids. (A) (B) U937 cells were infected with MuV at an MOI of 0.01 and treated with
increasing doses of retinol or all-trans retinoic acid (ATRA) as indicated. Whole cell lysates were harvested after 48 hours and viral titers were
measured by TCID50. (C) (D) RNA was extracted from parallel U937 cultures treated with increasing doses of retinol or ATRA and analyzed for
RAR-β expression by qPCR. Data presented reflect three experiments performed in triplicate (N = 3). *p < 0.05, **p < 0.01.
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of increased expression in response to MuV + ATRA
(data not shown). In addition to the regulation of ISG
expression, treatment of MuV infected U937 cells with
ATRA also increased STAT1 activation as indicated by
phosphorylation of tyrosine 701 (Figure 2G).
The increased expression of these ISGs can be attributed
to the increased activation of the type I IFN pathway.
When a monoclonal antibody specific to IFNα/β receptor
1 was used to prevent IFN signalling during MuV+ATRA
treatment, ISG mRNA expression was blocked, as demon-
strated by RIG-I mRNA (Figure 2H). This observation
demonstrates that IFN signalling is required for the
retinoid-MuV antiviral response.
Functional nuclear retinoid receptors mediate antiviral
activity of retinoids
To determine whether the antiviral activity of retinoids
requires nuclear receptor signalling, we utilized the
well-characterized NB4/R4 cell model (retinoid responsive
versus retinoid unresponsive) [54]. NB4 cells respond to
ATRA at pharmacologic concentrations, while the NB4
subclone R4 is completely resistant, regardless of the
concentration [54,55]. Both NB4 and R4 cells were readily
infected with MuV. In NB4 cells, 1 μM of ATRA was able
to inhibit MuV output but had no effect in R4 cells
(Figure 3A). At this concentration, the level of inhibition
observed was unlikely due to retinoid-driven differentiation
of the NB4 cells [46,48]. Like the U937 cells, expression ofthe ISG, IRF-1, was also increased in NB4 cells exposed
to ATRA alone but was higher in cells exposed to
MuV+ATRA infection (Figure 3B). IRF-1 mRNA expression
was very low during MuV infection alone in this
model. In the retinoid-unresponsive R4 cells, IRF-1
expression was not seen either with ATRA treatment alone
or in response to MuV+ATRA (Figure 3B). Exogenous
IFNβ treatment alone was not able to induce the expression
of IRF-1 in either cell line, suggesting the requirement of
ATRA for IRF-1 expression.
RIG-I mRNA expression was also significantly increased
by the combined treatment of MuV +ATRA in NB4 cells
(Figure 3C). Both MuV alone and ATRA alone increased
the expression of RIG-I over mock treatment, but the
expression was greatly enhanced by combined treatment.
Neither ATRA, nor MuV +ATRA induced the expression
of RIG-I mRNA in R4 cells (Figure 3C). When treated
with exogenous IFNβ, both NB4 and R4 cells increased
the expression of RIG-I mRNA suggesting that IFN signal-
ling is functional in both cell lines (Figure 3C). Expression
of other ISGs, including IRF-7 and MDA-5, showed a
similar pattern of up-regulation in NB4 cells and no
response in R4 cells (data not shown).
As a further confirmation of the role of RARα mediated
signalling in the retinoid-MuV antiviral response, treat-
ment of U937 cells with RO 41–5253, a specific RARα
antagonist, reversed the impact of ATRA on MuV
replication and reduced the expression of the ISGs in
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Figure 2 Type I interferon signaling is required for the induction of the retinoid anti-MuV response. U937 cells were infected with MuV at
an MOI of 0.01 and treated with 1 μM ATRA or DMSO. 48 hr post-infection, RNA was extracted and analyzed for IFNα1 (A), IFNβ (C), IRF-1 (E) and
RIG-I (F) expression by qPCR. Supernatants were analyzed by ELISA for IFNα1 (B) or IFNβ (D) protein. (G) U937 cells were treated with increasing
doses of ATRA (0-1000nM) and either mock infected or infected with MuV at an MOI 0.01. Protein was isolated from whole cell extracts and
analyzed by western blot for phospho-STAT1 (Y701), total STAT1 or β-actin. (H) U937 cells were infected with MuV at an MOI of 0.01 and treated
with 1 μM ATRA or DMSO and isotype control antibody or IFNAR2 antibody. 24 hr post-infection RNA was extracted and analyzed for RIG-I
expression by qPCR. Data presented reflect three experiments performed in triplicate (N = 3). *p < 0.05, **p < 0.01, ***p < 0.001.
Soye et al. Virology Journal 2013, 10:337 Page 4 of 13
http://www.virologyj.com/content/10/1/337RIG-I is required for the retinoid-induced antiviral
response
RIG-I is both retinoid responsive and IFN stimulated. It
was clearly up regulated in our in vitro model systems in
response to MuV +ATRA (Figures 2F, 3C). To investigate
the requirement of RIG-I signalling in the cellular response
to combined MuV+ATRA exposure, we used the Huh7
cell line, which is derived from a human hepatocellularcarcinoma and has been used extensively in hepatitis C
virus (HCV) research [56,57]. Of particular interest for our
studies, an Huh7 subclone (Huh7.5) has a point mutation
in the first CARD domain of RIG-I, rendering the protein
non-functional [57,58].
We turned to the Huh7/7.5 model to demonstrate the
importance of RIG-I rather than using RNA interference












Figure 3 Retinoid signaling is required for the inhibition of
MuV in vitro. NB4 and R4 cells were infected with MuV at an MOI
of 0.01, treated with 1 μM ATRA or DMSO and/or treated with
1000 U/mL IFNβ (PBL Interferon Source, New Jersey) as indicated.
(A) Whole cell lysates were harvested after 48 hours and viral titers
were measured by TCID50. RNA was extracted and analyzed for
IRF-1 (B) and RIG-I (C) expression by qPCR. Data presented reflect
three experiments performed in triplicate (N = 3). *p < 0.05,
**p < 0.01, ***p < 0.001.
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induce the expression of RIG-I and other interferon
stimulated genes (data not shown, also demonstrated
in [59,60]). In MuV infected Huh7 cells treated with
ATRA, virus output was significantly reduced (Figure 4A)
but ATRA had no effect on MuV replication in the
Huh7.5, RIG-I non-functional cells (Figure 4A).
It has recently been demonstrated that RIG-I comple-
mentation in Huh7.5 cells can restore the IRF3 pathway,
making these cells less permissive to Sendai virus
(SeV) infection [58]. This observation suggests that the
non-functional RIG-I encoded in the Huh7.5 cells can be
complemented by exogenous expression of the protein.
When RIG-I was transfected into the Huh7.5 cells,
inhibition of MuV replication was restored (Figure 4B).
These data demonstrate the requirement of RIG-I in
the retinoid-MuV antiviral response.Antiviral response is created in uninfected bystander cells
To determine whether or not a bystander effect was induced
following MuV infection, we repeated key experiments using
0.02 μm-pore membrane transwell tissue culture inserts
(depicted in [48] and [47]). In these experiments, the
inner-chamber U937 cells could be exposed to the products
of infection in the outer-chamber cells without direct
contact with either MuV itself or the MuV-infected
cells. We confirmed that MuV was not able to cross
the membrane by TCID50 assay of the inner-chamber
cells in each experiment.
ATRA-stimulated ISG expression was just as strong in
the inner-chamber (uninfected) as the outer-chamber
(infected) cells despite the absence of active infection.
Specifically, we found strong up-regulation of mRNA
expression for IRF-1 (Figure 5A) and RIG-I (Figure 5B),
as well as MDA-5 and IRF-7 (data not shown), in the
inner-chamber cells.
When the supernatant (or conditioned media) from
the inner-chamber bystander U937 cells was applied
to fresh cells, we observed a striking induction in the
expression of these same ISGs as shown for RIG-I
(Figure 5C).Bystander cells are protected from infection
To determine whether or not the uninfected inner-chamber,
bystander cells would have reduced susceptibility to
future infection these cells were harvested and challenged
with MuV at an MOI of 0.1 immediately following incuba-
tion in the transwell. Compared with control cells not
treated with ATRA and exposed to the products of MuV
infection, the inner-chamber cells were relatively resistant
to MuV replication (one log reduction in MuV titres pro-
duced, Figure 6A). This relatively refractory state persisted




Figure 4 RIG-I is required for the inhibition of MuV by retinoids. (A) Huh7 and Huh7.5 cells were infected with MuV at an MOI of 0.01 and
treated with 1 μM ATRA or DMSO. Whole cell lysates were harvested after 48 hours and viral titers were measured by TCID50. (B) Huh7.5 cells
were transfected with mock, pcDNA3.1 or pRIG-I-myc and incubated overnight. Following transfection, the cells were infected with MuV at an
MOI of 0.01 and treated with 1 μM ATRA. Whole cell lysates were harvested after 48 hours and viral titers were measured by TCID50. Western
blotting was not performed since Huh7.5 cells produce a defective RIG-I protein that cannot be distinguished from the wild-type protein by
commercially-available antibodies. Data presented reflect two experiments performed in triplicate (N = 2). ***p < 0.001.
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bystander U937 cells is short lived.
When inner-chamber bystander cells treated with ATRA
and exposed to the products of MuV infection were chal-
lenged with MeV at an MOI 0.1 MeV replication was also
reduced by at least 1 log compared to untreated controls
or cells treated with only ATRA or exposed to the products
of outer-chamber MuV infection (Figure 6C). The antiviral
state induced in these cells was not virus-specific.
Discussion
The potential role of individual micronutrients in specific
infectious diseases has been the subject of considerable
interest for decades (reviewed in [61]). To our knowledge,
retinol (Vitamin A) is currently the only micronutrient
routinely used to ‘treat’ a viral disease. In fact, both
vitamin A supplementation and therapy appear to have
significant clinical benefit in natural MeV infection
[16–19,21]. However, the effects of vitamin A on viral
infections have been highly variable and at times,
completely contradictory.
Although reduced mortality from diarrheal disease
is associated with vitamin A supplements in children
of the developing world this benefit appears to be
due largely to milder bacterial infections [14,62,63]. In
Mexican children receiving vitamin A supplements, the
incidence of Norovirus diarrhea was reduced but gut viral
titres and the period of virus shedding in these children
were both significantly increased [64].
In human immunodeficiency virus (HIV) infection,
pre-antiretroviral treatment (ART) studies suggested
that low serum retinol levels were associated with rapid
progression of acquired immunodeficiency syndrome
(AIDS) but later studies showed little-to-no impact
of supplements on disease progression or survival(reviewed in [65]). Perinatal vitamin A supplements
in HIV-positive women can improve the survival of the
seronegative children but can increase mother-to-child
HIV transmission [65], possibly through increased viral
loads in breast milk [66]. In vitro, retinoids have been
found to both increase and decrease HIV replication in
different model systems [67,68].
Patients infected with Hepatitis C virus (HCV) and
treated with 9-cis retinoic acid or ATRA in combination
with pegylated IFNα have lower viral loads [69,70]. In
contrast, supplements do not increase viral clearance
in human papilloma virus (HPV)-infected women [71].
Both vitamin A supplementation and treatment have
either no or negative effects on respiratory tract infections
including the common paramyxovirus, respiratory syncytial
virus (RSV) [72–74]. Studies with another paramyxovirus
have shown that vitamin A deficient chickens suffer
increased morbidity from Newcastle disease virus (NDV)
[75–77]. Using the paramyxovirus most closely related to
measles, our group has demonstrated that canine distemper
virus (CDV)-infected ferrets treated with vitamin A develop
less severe disease [78]. In aggregate, these observations
suggest that vitamin A and its derivatives may play
an important role in antiviral responses but demonstrate
clearly that mechanistic studies are essential to fully
understand and exploit this potential.
Previously we have shown that retinoids can inhibit
MeV replication in vitro via retinoid nuclear receptor
activating type I IFN signalling [46,48]. We hypothesized
that ATRA treatment during MuV infection may also
inhibit MuV replication in vitro. We further sought to
determine if the retinoid-MuV antiviral response would
require type IFN signalling, RAR signalling and functional
RIG-I. The current work demonstrates that ATRA
















Figure 5 Retinoids induce an anti-MuV state in the uninfected,
bystander cells. U937 cells were infected with MuV at an MOI of
0.01 in the presence of 1 μM ATRA or DMSO. Transwell membrane
inserts with 0.02 μm pores were used to separate the infected cells
in the outer chamber from the uninfected, bystander cells in the
inner chamber [48]. Cells from control wells (no membrane insert),
outer and inner chamber bystander cells were harvested after
48 hours and IRF-1 (A) and RIG-I (B) mRNA were measured by qPCR.
As indicated on the Figure, outer chamber cells infected by MuV are
represented by open bars and inner chamber (uninfected) cells are
represented by the filled bars. (C) Conditioned media from the control
and transwell inner chambers were applied to fresh U937 cells. After
24 hours of incubation with the conditioned media, RNA was extracted
and RIG-I expression was analyzed. Data presented reflect three
experiments performed in triplicate (N = 3). * p <.02,**p < 0.01.
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multiple members of the Paramyxovirus family or more
broadly, to viruses that are detected by RIG-I. Figure 7
depicts our current understanding of retinoid action on
Paramyxovirus infection. In Figure 7A, ATRA alone has
no protective capacity on initially infected cells. These
cells will produce the same amount of virus as untreated
cells and ultimately, will die as a result of infection.
However, the initially uninfected cells in the culture are
primed for ISG expression by ATRA treatment through
activation of the nuclear retinoid receptors. In Figure 7B,
retinoid-primed cells effectively up-regulate ISG expression
and type I IFN production upon viral infection. The
combination of type I IFN and ATRA induces RIG-I
expression in uninfected bystander cells, further improving
the innate anti-viral response. ATRA is essential for
initiating positive feedback through RIG-I activation
and type I IFN pathways, which protects uninfected cells.
In the current work, we used a variety of in vitro models
to extend our central observation of retinoid-induced anti-
viral effects to MuV (Figures 1A, 1C, 3A, 4A). Although the
cell lines used in this work varied in their overall sensitivity
to retinoids (NB4 > U937 > Huh7>> R4), all supported the
growth of MuV. Retinoid-induced suppression of MuV
replication could be demonstrated in all but the R4
cells. Retinol (ROH) is the form of vitamin A found
in the circulation at concentrations up to 2 μM [79].
The degree of inhibition of MuV replication was much
greater using ATRA, a natural derivative of ROH and
ligand that binds directly to nuclear receptors. ATRA is
generally found in the intracellular space, but can be found
in the serum in the 5–10 nM range [79]. As a result, we
believe the mechanisms that we have documented in vitro
to be potentially active in vivo. Indeed, the outcome of any
infection is essentially a ‘race’ between pathogen replication
and the developing immune response. In this context, it is
plausible that the modest reduction in the rate of MuV














Figure 6 Antiviral state is short-lived and virus non-specific. (A)
The inner chamber bystander cells were harvested and challenged
with MuV at an MOI of 0.1. Whole cell lysates were harvested after
48 hours and viral titers were measured by TCID50. (B) To assess the
duration of the anti-viral state, U937 cells were suspended in TW
inner-chamber conditioned media and incubated for the indicated
time at 37°C then challenged with MuV at an MOI of 0.1. Whole cell
lysates were harvested after 48 hours and viral titers were measured
by TCID50. (C) The inner chamber bystander cells were harvested
and challenged with MuV at an MOI of 0.1. Whole cell lysates were
harvested after 48 hours and viral titers were measured by TCID50.
Data presented are representative of two-three experiments
performed in triplicate (N = 2-3). *p < 0.05, **p < 0.01.
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disease, as occurs with vitamin A treatment in natural
MeV infection. To our knowledge, there has not yet been
any attempt to use retinol (or other retinoids) to modulate
the course of mumps infection. Unfortunately, there is no
animal model for mumps in which this possibility can be
directly tested.
The antiviral state created by the combination of
MuV infection and ATRA treatment was ultimately
generated by the expression of type I interferon. We
have demonstrated that the combination of MuV +ATRA
leads to transcription of IFN genes and at least additive
increases in IFNα1 and IFNβ levels in culture supernatants,
as well as enhanced transcription of ISGs (Figure 2A-F).
Increasing doses of ATRA in the context of MuV infection
led to marked increases in STAT1 activation (Figure 2G)
and, when type I IFN signalling was blocked, the antiviral
state is lost (Figure 2H). MuV normally escapes type I IFN
control by targeting STAT1 for proteasomal degradation.
Variations in the V protein sequence can decrease the
efficiency of proteosomal targeting of STAT1, [80] resulting
in differing sensitivity to type I IFNs and potentially
the IFN dependent antiviral state produced by retinoid
treatment. We are currently collecting wild-type MuV
isolates to correlate retinoid sensitivity with V protein
sequence to better understand this apparent paradox. At
the current time, we also cannot fully explain differences in
ATRA-induced up-regulation of RIG-I expression between
the U937 and NB4 cells other that to postulate greater
retinoid sensitivity in the RIG-I promoter of the former
line. It is also possible that the timing of sample collection
contributed to these results. Similarly, the timing of
sampling may underlie the up-regulation of RIG-I mRNA
in NB4 cells in response to IFNβ stimulation despite
the apparent absence of IRF-1 induction (Figure 3B/C).
Time course studies are currently underway to address
these issues.
We further demonstrate that nuclear retinoid receptor
signalling was also central to the antiviral effect of retinoids
against MuV. Although it is possible that more than one
nuclear receptor may be involved, our current data suggest
that RARα plays an important role in mediating the
antiviral effects against MuV. In our NB4/R4 model, RAR
signalling was not only required for the antiviral effect
(Figure 3A), it was essential for the expression of ISGs that
contribute to the antiviral response (Figure 3B-C).
Finally, we demonstrate a similar retinoid signalling
mechanism in response to MuV +ATRA (Figures 2E, 3C,
Figure 4A). Most convincing, we have shown that
overexpression of RIG-I in Huh7.5 cells with non-functional
RIG-I signalling, can reinstate the retinoid-induced
inhibition of MuV. The results in the Huh7.0/7.5 model
are particularly interesting because MuV output does not
differ greatly at 48 hours, suggesting that intact RIG-I
Figure 7 Retinoid action during paramyxovirus infection. (A) 1) Jak/STAT signaling is inhibited as a result of viral infection and ATRA
treatment is unable to effectively promote unregulation of ISGs and type I IFN production. 2) Cells exposed to the products of the primary
infection and primed with ATRA can more efficiently secrete type I IFN upon infection. (B) 3) Exposure to ATRA and type I IFN in the supernatant
signals through the Jak/STAT pathway with the combination of nuclear localization of STAT1/2 heterodimer and activation of the RAR/RXR
complex results in the transcription of multiple ISGs, importantly IRF1. For simplicity, only IFNα and its receptor IFNAR1/2 are shown to promote
Jak/STAT signaling. 4) RIG-I expression is greatly up-regulated under these conditions, by IRF1 binding to the interferon response element (IRE) on
its promoter. 5) Increased cytoplasmic quantities of RIG-I provide protection in the bystander cell upon virus infection. RIG-I detects viral RNA and
associates with the adaptor protein MAVS, which initiates downstream activation of NFκB and IRF3/7. Nuclear translocation to their respective
promoter elements induces transcription of antiviral genes, i.e., type I IFN and IRF1/7 production. It is not clear what role the second cytoplasmic
RNA helicase (mda5) plays in this cascade although mda5 has been implicated in responses to several Paramyxoviridae. 6) These proteins feedback
onto their respective pathways and promote RIG-I expression, further improving the antiviral state of the cell. 7) Increased production of type I IFN from
the retinoid-primed bystander cell provides both an autocrine and paracrine signal to further protect the uninfected cells in culture.
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viral replication. However. transfection of a functional
RIG-I clearly restores retinoid responsiveness in this
model. At least some of this paradox may be explained by
the 48-hour time-point used for most experiments. Indeed,
MuV output was lower in the Huh7.0 than Huh7.5 cells for
the first 24–36 hours (data not shown). The 48 hour
time-point was chosen for our experiments because
retinoid effects were most obvious at this time. These find-
ings are very similar to our observations with measles virus
in the Huh 7.0/7.5 model where transfection of a dominant
negative RIG-I eliminates the anti-viral activity of retinoids
in the Huh 7.0 cells and transfection of a functional RIG-I
gene into Huh 7.5 cells restores activity [47].
The Huh7.0/7.5 data are also intriguing because they
suggest a larger role for RIG-I in defending against MuV
than would have been predicted from the literature to
date. It is widely thought that the double-stranded RNA
sensor mda-5 is the primary target of the MuV V protein[81,82] and that RIG-I may respond primarily to
Paramyxovirus defective interfering particles [83]. For
several Paramyxoviruses, mda-5 signalling is inhibited
by direct binding of the V protein and conserved residues
in the helicase [82]. More recent data raises the possibility
that Paramyxovirus V proteins may also target RIG-I
indirectly by binding to laboratory of genetics and
physiology 2 (LGP2) [84] Mutations in the carboxy-terminal
domain of the V protein can result in a reduction or total
loss of this interference [81]. In both NB4 and U937
cells, mda-5 expression is also increased by ATRA
alone (data not shown). We are currently collecting
wild-type (WT) MuV isolates to assess their susceptibility
to retinoid-induced suppression and to correlate this sup-
pression with V protein mutations. Our preliminary data
(4 low-passage isolates to date) suggest that sensitivity to
retinoid-induced suppression varies widely in WT MuV
(50% suppressible) It is also interesting that retinoid sensi-
tivity has been maintained in the two initially sensitive
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in our laboratory.
The antiviral state created by MuV + ATRA was most
profound in the initially uninfected bystander cells
(Figure 5A-B) and could be transferred to fresh cells
via the conditioned media leading to up-regulation of
ISG expression (Figure 5C). Not surprisingly, since
type I IFN responses are innate and non-specific, cells
exposed to conditioned media from MuV +ATRA cells
were relatively resistant to subsequent challenge with
either MuV or MeV for less than 12 hours (Figure 6A-C).
This last observation is consistent with the immediate and
short-lived antiviral effects of type I IFNs [85].
The Paramyxoviridae including MeV, MuV, RSV, CDV,
phocine distemper virus, Nipah virus and Hendra virus
are among the most important human and animal
pathogens. Commercial vaccines are not yet available
for many of these viruses, and antiviral drugs are typically
of little use [86]. Some of these viruses can have extraordin-
arily high mortality rates (for example, CDV in naïve seals
and dogs, Nipah and Hendra viruses in man) [87].
The clinical evidence of benefit from retinoid therapy
of MeV infection in children and CDV infection in
ferrets is strong [17–19,78]. Our in vitro data suggest
that ATRA may be far more potent that retinol in
mediating antiviral effects. Our mechanistic studies in
different tissue culture models of MuV infection suggest
that common signalling pathways mediate these effects
[46–48]. However, high doses of vitamin A in children
with RSV infection have no benefit and may even cause
harm [74,88]. In aggregate, these clinical and laboratory
observations support further studies of the efficacy and
mechanism of action of retinoids against a wider range of
respiratory viruses in more sophisticated animal models,
such as primates, or even clinical studies. It would be of
particular interest to use retinoids other than retinol,
ATRA in particular, in these latter studies to achieve more
effective inhibition of viral replication. This conclusion is
further supported by a recent study demonstrating that
several synthetic retinoid analogues have much greater
capacity to interfere with human herpes virus 8 (HHV8)
replication in vitro than retinol [89].
Conclusions
In conclusion, this work has demonstrated that MuV
can be inhibited in vitro by retinoids. This antiviral
effect required RAR signalling, type I IFN signalling and
functional RIG-I. The antiviral response was created in
the initially uninfected bystander cells and was both
short-lived and cross-protective against subsequent
MuV or MeV challenge. This is the first work to
demonstrate the antiviral effect of vitamin A on MuV
and may contribute to better treatment options for
MuV. We propose that IRF-1 is recruited to the RIG-Ipromoter under the influence of ATRA alone, and is
required for the induction of RIG-I (47). In these models
systems therefore, ATRA inhibits MuV replication through
the RARα-dependent regulation of RIG-I and IRF-1 and via
an IFN feedback loop.
Methods
Cells, reagents and viruses
All cell cultures were maintained at 37°C in a 5% CO2
humidified incubator. U937 (ATCC, #CRL-1593.2), NB4
(M. Lanotte, INSERM UMR-S 1007, Paris, France) and
R4, Huh7 and Huh7.5 (courtesy C. Richardson, Dalhousie
University, Halifax, NS), Vero cells (ATCC, #CCL-81) were
maintained as described in [47]. Retinol and All-trans
retinoic acid (ATRA) (Sigma-Aldrich Fine Chemicals,
Oakville, ON) stock solutions of 10−2 M were prepared in
100% DMSO and further dilutions were performed using
RPMI. DMSO at equivalent final dilutions was used in all
experiments as a control. All retinoids were stored in
opaque eppendorf tubes at −80°C. The Jones MuV strain
(ATCC, #VR-365) is a tissue culture-adapted virus that
was, according to the supplier’s web-site, extensively
passaged in chicken embryos and Vero cells prior to
purchase. Our MuV stock was initially plaque purified and
then grown by infecting Vero cells with a maximum
passage of three times from the original purchase
(ATCC, #CCL-81) at a multiplicity of infection (MOI)
of 0.001 at 33°C in a Cell-Stack 10 (Corning, Corning,
NY). Harvested virus was concentrated by centrifugation
at 15,752 x g for seven hours at 4°C in a fix-angle rotor,
the pellet was resuspended in RPMI with gentle pipetting.
The Chicago-1 MeV strain is a tissue culture-adapted
genotype D3 virus (courtesy of W. Bellini, CDC, Atlanta,
GA). MeV stock was grown as described in [47].
Cell culture infections
Cell lines were infected with MuV at the indicated MOIs.
Media was removed and virus diluted in Hanks’ Balanced
Salt Solution with calcium and magnesium (Wisent,
St-Bruno, QC). The virus was incubated with the cells
for 1.5 hours, with gentle rocking at 15-minute intervals.
The virus was removed and cells were resuspended in
RPMI 1640 supplemented as previously described [46–48]
using the specific MOIs and time points indicated in the
figure legends and incubated at 37°C/5% CO2.
Quantitative RT-PCR
RNA was extracted using Trizol (Invitrogen by Life
Technologies, Burlington, ON) as per the manufacturer’s
instructions, and treated to remove possible genomic DNA
contamination with Turbo DNAse (Ambion, Austin, TX).
For experiments in which antibodies were used to block type
I IFN signalling, an RNeasy Mini kit was used to extract
RNA (Qiagen, Mississauga, ON). Equal quantities of RNA
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using random primers. FAM-labelled TaqMan primer-probe
assays for the following genes were obtained from
ABI (Applied Biosystems by Life Technologies, Carlsbad
CA): RIG-I, RARβ and IRF-1. The level of gene expression
in untreated cells was used for calibration. Vic-labeled
hGAPDH was used as the endogenous control.Transwell
Transwell experiments (TW) were performed as previously
described [47,48]. Briefly, TW membranes inserts with 0.02
μM pores served to separate infected cells in the outer
chamber from the uninfected bystander cells of the inner
chamber. Wells with no transwell inserts were used for
control cultures. Preliminary experiments demonstrated
that the presence/absence of the TW membrane had no
impact on measured outcomes under control conditions.Conditioned media
Supernatants were collected from TWs and used to treat
fresh U937 cells. After 24 hours of incubation with the
TW conditioned media, RNA was extracted and RT
PCR performed. These samples were analyzed by qPCR
for the expression of RIG-I.Blocking antibody
Supernatants were collected from TWs and used to treat
fresh U937 cells. These fresh cells were treated with anti-
IFNAR2 blocking antibody (20 μg/μL, PBL Biomedical
Laboratories, Piscataway, NJ) or isotype control antibody
for one hour before infection and for the subsequent
24-hour incubation with the conditioned media. These
samples were analyzed by qPCR for the expression of RIG-I.Western blotting
Cells were infected with MuV and/or treated with ATRA
at the indicated doses. 48 hours post infection, protein
was harvested as previously described in [47]. The
membranes were incubated in 5% non-fat milk or 5%
BSA for 1 hour and incubated overnight at 4°C with
primary antibody. Primary antibodies used were against
phospho-STAT1 (Y701) (1/1000, BD Bioscience), Total
STAT1 (1/1000, BD Bioscience) and β-actin (1/10000,
Sigma). Following overnight incubation, membranes
were washed three times for 10 minutes in TBS/0.1%
Tween, incubated with secondary antibody (1/10000,
GE Healthcare) at room temperature for 30 minutes,
and washed three times for 10 minutes. The peroxidase-
conjugated secondary antibodies were developed using a
chemiluminescence kit according to the manufacturer’s
instructions (GE Healthcare).Transfection
Huh 7.5 cells were seeded at 1.5 × 105 cell/mL, then were
transfected with 3 μg of the RIG-I construct in a pcDNA3
plasmid (gift from J. Hiscott) or empty vector using a 3:1
ratio of FuGENE 6 (Roche, Toronto, ON) as per the
manufacturer’s instructions. At 18 hours post-transfection,
cells were infected with MuV MOI 0.01 and at 48 hours
post infection the cells and supernatants were quantified
using plaque assay as previously described [46].
Viral challenge of bystander cells
Bystander cells from the TW inner chambers were pooled
according to treatment and resuspended in Hanks’
Balanced Salt Solution with calcium and magnesium
(Wisent, St-Bruno, QC). Cells are infected with MuV
or MeV at MOI 0.1 as described above and previously
[46–48]. These cells were resuspended in RPMI 1640
(Wisent, St-Bruno, QC) supplemented with 10% heat-
inactivated FBS (Wisent, St-Bruno, QC) and 0.1%
gentamicin and incubated for the indicated time at
37°C/5% CO2.
Tissue culture infectious dose50 (TCID50)
MuV concentrations were quantified by TCID50. Briefly,
Whole cells and supernatant were frozen at −80°C to
lyse cells, samples were defrosted on ice, then serially
diluted in Minimum Essential Medium Eagle (Wisent,
St-Bruno, QC) supplemented with 3% heat-inactivated FBS
(Wisent, St-Bruno, QC) and 0.1% gentamicin. Supernatants
were not analysed separately in this series of experi-
ments. Diluted virus was applied to Vero cells in 3%
heat-inactivated FBS (Wisent, St-Bruno, QC) and 0.1%
gentamicin in 96-well plates. The virus is incubated
with the cells for 5 days at 37°C/5% CO2. Syncytium
formation was scored and TCID50 was calculated
using the Karber method [90,91].
Elisa
U937 cells were infected at an MOI of 0.01 with the indi-
cated virus. At 48 hours post-infection, supernatant IFNα1
and IFNβ were measured by ELISA (PBL Interferon Source,
Piscataway, NJ) as per the manufacturer’s instructions.
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